KR950701820A - PROPHYLAXS AND TREATMENT OF SEPSIS AND SEPSIS-ASSOCIATED COAGULATION DISORDERS - Google Patents

PROPHYLAXS AND TREATMENT OF SEPSIS AND SEPSIS-ASSOCIATED COAGULATION DISORDERS

Info

Publication number
KR950701820A
KR950701820A KR1019940704533A KR19940704533A KR950701820A KR 950701820 A KR950701820 A KR 950701820A KR 1019940704533 A KR1019940704533 A KR 1019940704533A KR 19940704533 A KR19940704533 A KR 19940704533A KR 950701820 A KR950701820 A KR 950701820A
Authority
KR
South Korea
Prior art keywords
sepsis
patient
effective amount
therapeutically effective
administering
Prior art date
Application number
KR1019940704533A
Other languages
Korean (ko)
Inventor
제이. 브로즈 조지
Original Assignee
로저 에이. 윌리암스
지. 디. 썰 앤드 컴파니
원본미기재
몬산토 컴파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로저 에이. 윌리암스, 지. 디. 썰 앤드 컴파니, 원본미기재, 몬산토 컴파니 filed Critical 로저 에이. 윌리암스
Publication of KR950701820A publication Critical patent/KR950701820A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

LACI의 치료적으로 유효한 양을 폐혈증에 걸리거나 또는 걸리기 쉬운 환자에게 투여하는 것을 특징으로 하는 LACI의 사용방법이 주어진다.A method of using LACI is given wherein a therapeutically effective amount of LACI is administered to a patient with or susceptible to pulmonary disease.

Description

패혈증 및 패혈증-연관 응고장애의 예방 및 치료 (PROPHYLAXS AND TREATMENT OF SEPSIS AND SEPSIS-ASSOCIATED COAGULATION DISORDERS)PROPHYLAXS AND TREATMENT OF SEPSIS AND SEPSIS-ASSOCIATED COAGULATION DISORDERS

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (11)

패혈증에 걸리거나 또는 걸리기 쉬운 환자에게 LACI를 함유하고 본질적으로 헤파린이 없는 조성물의 치료적으로 유효한 양을 투여하는 것으로 이루어지는 LACI의 사용방법.A method of using LACI consisting of administering to a patient with or susceptible to sepsis a therapeutically effective amount of a composition containing LACI and essentially heparin free. LACI를 함유하고 본질적으로 헤파린이 없는 조성물의 치료적으로 유효한 양을 그것이 필요한 환자에게 투여하는 것으로 이루어지는 패혈증의 치료방법.A method of treating sepsis, comprising administering to a patient in need thereof a therapeutically effective amount of a composition containing LACI and essentially free of heparin. LACI를 함유하고 본질적으로 헤파린이 없는 조성물의 치료적으로 유효한 양을 그것이 필요한 환자에게 투여하는 것으로 이루어지는 패혈증-연관 응고장애의 치료방법.A method of treating sepsis-associated coagulation disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a composition containing LACI and essentially free of heparin. 제3항에 있어서, 상기의환자는 패혈증에 걸린 환자인 것을 특징으로하는 방법.The method of claim 3, wherein the patient is a patient with sepsis. 제3항에 있어서, 상기의 패혈증-연관 응고장애가 DIC인 것을 특징으로 하는 방법.4. The method of claim 3, wherein said sepsis-associated coagulation disorder is DIC. LACI를 함유하고 본질적으로 헤파린이 없는 조성물의 치료적으로 유효한 양을 그것이 필요한 환자에게 투여하는 것으로 이루어지는 패혈증-연관 응고장애의 예방방법A method of preventing sepsis-associated coagulation disorder comprising administering to a patient in need thereof a therapeutically effective amount of a composition containing LACI and essentially free of heparin. 제6항 에있어서, 상기의 환자는 패혈증에 걸리기 쉬운 환자인 것을 특징으로 하는 방법.The method of claim 6, wherein the patient is susceptible to sepsis. LACI를 함유하고 본질적으로 헤파린이 없는 조성물의 치료적으로 유효한 양을 그것이 필요한 환자에게 투여하는 것으로 이루어지는 패혈증-연관 DIC의 예방방법.A method of preventing sepsis-associated DIC comprising administering to a patient in need thereof a therapeutically effective amount of a composition containing LACI and essentially free of heparin. 제8항에 있어서, 상기의 환자는 패혈증에 걸리기 쉬운 환자인 것을 특징으로 하는 방법.The method of claim 8, wherein the patient is susceptible to sepsis. LACI를 함유하고 본질적으로 헤파린이 없는 조성물의 치료적으로 유효한 양을 그것이 필요한 환자에게 투여하는 것으로 이루어지는, 패혈증에 걸리거나 또는 걸리기 쉬운 환자의 치료방법.A method of treating a patient with or susceptible to sepsis, comprising administering to a patient in need thereof a therapeutically effective amount of a composition containing LACI and essentially free of heparin. LACI의 치료적으로 유효한 양을 그것이 필요한 환자에게 투여하느 것으로 이루어지는, 패혈증에 걸리거나 또는 걸리기 쉬운 환자의 생존을 증가시키는 방법.A method of increasing survival of a patient with or susceptible to sepsis, which comprises administering a therapeutically effective amount of LACI to a patient in need thereof. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940704533A 1992-06-11 1993-06-11 PROPHYLAXS AND TREATMENT OF SEPSIS AND SEPSIS-ASSOCIATED COAGULATION DISORDERS KR950701820A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89713592A 1992-06-11 1992-06-11
US07/897,135 1992-06-11
US2047293A 1993-02-22 1993-02-22
US08/020,472 1993-02-22
PCT/US1993/005409 WO1993025230A1 (en) 1992-06-11 1993-06-11 Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders

Publications (1)

Publication Number Publication Date
KR950701820A true KR950701820A (en) 1995-05-17

Family

ID=26693480

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940704533A KR950701820A (en) 1992-06-11 1993-06-11 PROPHYLAXS AND TREATMENT OF SEPSIS AND SEPSIS-ASSOCIATED COAGULATION DISORDERS

Country Status (4)

Country Link
KR (1) KR950701820A (en)
AU (1) AU4408493A (en)
DK (1) DK140594A (en)
WO (1) WO1993025230A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
CA2194443A1 (en) * 1994-07-07 1996-01-25 Dana R. Abendschein Method of attenuating arterial stenosis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US6323326B1 (en) 1995-06-07 2001-11-27 Chiron Corporation Method of solubilizing, purifying, and refolding protein
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
AU2003200506B2 (en) * 1995-06-07 2007-01-18 G.D. Searle Llc Method of solubilizing, purifying and refolding protein and compositions comprising proteins and solubilizing agents
AU759412B2 (en) * 1995-06-07 2003-04-17 G.D. Searle & Co. Method of solubilizing, purifying and refolding protein and compositions comprising proteins and solubilizing agents
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6939716B2 (en) 2001-09-19 2005-09-06 Washington University Method for detecting conditions indicative of sepsis
EA200400548A1 (en) 2001-10-15 2005-06-30 Чирон Корпорейшн TREATMENT OF HEAVY PNEUMONIA THROUGH THE INTRODUCTION OF THE TISSUE FACTOR INHIBITOR (TFPI)
EP1654283B1 (en) 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Improved method of purifying tfpi and tfpi analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148890D0 (en) * 1990-06-19 1990-06-19 Novo Nordisk As PHARMACEUTICAL PREPARATION

Also Published As

Publication number Publication date
AU4408493A (en) 1994-01-04
WO1993025230A1 (en) 1993-12-23
DK140594A (en) 1994-12-08

Similar Documents

Publication Publication Date Title
KR950701820A (en) PROPHYLAXS AND TREATMENT OF SEPSIS AND SEPSIS-ASSOCIATED COAGULATION DISORDERS
KR950002785A (en) Parathyroid hormone and raloxyphene to increase bone mass
FI931097A (en) LAEKEMEDEL, DERAS FRAMSTAELLNING OCH ANVAENDNING VID BEKAEMPNING AV SMAERTOR OCH / ELLER INFLAMMATIONEN HOS MAENNISKOR OCH DJUR
KR950700060A (en) Application of 2-amino 6-trifluoromethoxy benzothiazole (riluzole) for obtaining a drug useful in the treatment of motor neuron diseases)
BR9811825A (en) Use of lactobacillus to reduce the level of fibrinogen in the blood
KR930012022A (en) Modafinil for brain tissue protection
KR900701261A (en) Obesity Treatment
IT1224795B (en) USE OF ACETYL D-CARNITINE IN THE THERAPEUTIC TREATMENT OF GLAUCOMA AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT
PT92131A (en) PROCESS FOR THE PREPARATION OF MEDIA FOR TRANSDERMIC APPLICATION OF GESTODENO
ES2152998T3 (en) ANTI-COMPLEMENTARY AGENT OBTAINED FROM FUCANOS DE ALGAS PARDAS.
KR890011606A (en) Anticoagulant
KR910004187A (en) Treatment of Early Ejaculation with Cetralline
RU92016463A (en) APPLICATION OF DERIVATIVES OF TISSTINES FOR THE MANUFACTURE OF MEDICINES WITH IMMUNOMODING EFFECT, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS
KR920016088A (en) Treatment of lower urinary tract disease
KR920703041A (en) Ingredients and methods used to treat inflammatory or allergic diseases with pain
KR890011589A (en) Use of Benzamide
KR940018087A (en) 6-chloro-5-fluoro-3- (2-tenoyl) -2-oxindol-I-carboxamide as analgesic and anti-inflammatory agent
ITRM910002A0 (en) USE OF ACETYL L-CARNITINE IN THE THERAPEUTIC TREATMENT OF COMA AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT.
BR9811473A (en) Rhinoviruses infection inhibited by nitric oxide
PT92995A (en) METHOD FOR THE TREATMENT OF LEUCOCITE DYSFUNCTION WITH GM-CSF
KR880009661A (en) Use of blood coagulation factor XIII in humans for the treatment of ulcerative colitis
KR910015300A (en) Buspyron: Use for the treatment of sleep apnea
BR9204815A (en) TAURINE-BASED PHARMACEUTICAL COMPSOICATS FOR INHALATION ADMINISTRATION AND USE PROCESS
NO960545D0 (en) Treatment of adverse effects associated with the administration of extracellular hemoglobin
KR920011502A (en) Buzaijung-tang's improved herbal medicine to treat pain in the human nervous system

Legal Events

Date Code Title Description
N231 Notification of change of applicant
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid